董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Xiaochun Wang | 男 | Chairman of the Board | 42 | 未披露 | 未持股 | 2009-12-31 |
| Justin Yan Chen | 男 | Director | 44 | 未披露 | 未持股 | 2009-12-31 |
| Yongcun Chen | 男 | Independent Director | 44 | 未披露 | 未持股 | 2009-12-31 |
| Harry K. Genant | 男 | Independent Director | 67 | 未披露 | 未持股 | 2009-12-31 |
| David Ray White | 男 | Independent Director | 55 | 未披露 | 未持股 | 2009-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Xiaochun Wang | 男 | Chief Executive Officer | 42 | 未披露 | 未持股 | 2009-12-31 |
| Justin Yan Chen | 男 | Chief Operating Officer | 44 | 未披露 | 未持股 | 2009-12-31 |
| Ling Qin | 男 | Chief Technology Officer | 50 | 未披露 | 未持股 | 2009-12-31 |
| Charles Wang | 男 | Chief Financial Officer | 44 | 未披露 | 未持股 | 2009-12-31 |
董事简历
中英对照 | 中文 | 英文- Xiaochun Wang
-
Xiaochun Wang，董事会主席和首席执行官。1997年5月起他是Tongjitang Pharmaceutical董事长；2001年2月起，他是Tongjitang Distribution董事长。2006年6月到2008年12月，他是贵州同济堂中药种植有限公司董事长。1989年Wang毕业于西南政法大学法律专业。
Xiaochun Wang is the chairman of our board of directors and our chief executive officer. Mr. Wang has also been the president of Tongjitang Pharmaceutical since May 1997 and a director of Tongjitang Distribution since February 2001. Mr. Wang served as a director of Guizhou Tongjitang Traditional Chinese Medicines Planting Co., Ltd. from June 2006 to December 2008. Mr. Wang received his bachelor's degree in law from the Southwest University of Political Science and Law in China in 1989. - Xiaochun Wang，董事会主席和首席执行官。1997年5月起他是Tongjitang Pharmaceutical董事长；2001年2月起，他是Tongjitang Distribution董事长。2006年6月到2008年12月，他是贵州同济堂中药种植有限公司董事长。1989年Wang毕业于西南政法大学法律专业。
- Xiaochun Wang is the chairman of our board of directors and our chief executive officer. Mr. Wang has also been the president of Tongjitang Pharmaceutical since May 1997 and a director of Tongjitang Distribution since February 2001. Mr. Wang served as a director of Guizhou Tongjitang Traditional Chinese Medicines Planting Co., Ltd. from June 2006 to December 2008. Mr. Wang received his bachelor's degree in law from the Southwest University of Political Science and Law in China in 1989.
- Justin Yan Chen
-
Justin Yan Chen，2006年5月16日起担任公司董事长，2006年11月起担任首席运营官。2001年，Chen先生加入中国海淀集团，2004年，他担任项目投资的负责人，负责该公司在中国的投资项目。1999年他获得英国兰开斯特大学工商管理硕士学位，1988年获得对外经济贸易大学经济学学士学位。
Justin Yan Chen has been a director of our company since May 16 2006 and our chief operating officer since November 2006. In 2001 Mr. Chen joined China Haidian and in 2004 served as the head of Project Investment, responsible for the company's investment projects in China. Mr. Chen received his MBA from Lancaster University in the United Kingdom in 1999 and bachelor's degree in economics from the University of International Business and Economics in China in 1988. - Justin Yan Chen，2006年5月16日起担任公司董事长，2006年11月起担任首席运营官。2001年，Chen先生加入中国海淀集团，2004年，他担任项目投资的负责人，负责该公司在中国的投资项目。1999年他获得英国兰开斯特大学工商管理硕士学位，1988年获得对外经济贸易大学经济学学士学位。
- Justin Yan Chen has been a director of our company since May 16 2006 and our chief operating officer since November 2006. In 2001 Mr. Chen joined China Haidian and in 2004 served as the head of Project Investment, responsible for the company's investment projects in China. Mr. Chen received his MBA from Lancaster University in the United Kingdom in 1999 and bachelor's degree in economics from the University of International Business and Economics in China in 1988.
- Yongcun Chen
-
Yongcun Chen2009年4月成为本公司独立董事；自2006年6月15日起，他一直是我们公司的董事。2000年10月至2008年2月，陈先生是Silver Grant International Industries Limited（一家香港联交所上市的公司）的董事。自2000年起，陈先生一直担任Well Kent International Limited的总经理助理。1988年，陈先生获得了Tsinghua University工程学士学位和1992年获得硕士学位。陈先生拥有超过10年的金融和投资经验。
Yongcun Chen became an independent director of our company in April 2009 and he has been a director of our company since June 15 2006. From October 2000 to February 2008 Mr. Chen was a director of Silver Grant International Industries Limited, a public company listed on the Hong Kong Stock Exchange. Mr. Chen has been the assistant to general manager of Well Kent International Limited since 2000. Mr. Chen received his bachelor's degree in engineering in 1988 and master's degree in engineering in 1992 both from Tsinghua University. Mr. Chen has over 10 years' experience in finance and investment. - Yongcun Chen2009年4月成为本公司独立董事；自2006年6月15日起，他一直是我们公司的董事。2000年10月至2008年2月，陈先生是Silver Grant International Industries Limited（一家香港联交所上市的公司）的董事。自2000年起，陈先生一直担任Well Kent International Limited的总经理助理。1988年，陈先生获得了Tsinghua University工程学士学位和1992年获得硕士学位。陈先生拥有超过10年的金融和投资经验。
- Yongcun Chen became an independent director of our company in April 2009 and he has been a director of our company since June 15 2006. From October 2000 to February 2008 Mr. Chen was a director of Silver Grant International Industries Limited, a public company listed on the Hong Kong Stock Exchange. Mr. Chen has been the assistant to general manager of Well Kent International Limited since 2000. Mr. Chen received his bachelor's degree in engineering in 1988 and master's degree in engineering in 1992 both from Tsinghua University. Mr. Chen has over 10 years' experience in finance and investment.
- Harry K. Genant
-
Harry K. Genant，2007年3月21日起担任独立董事长。他是Synarc联合创始人。1998年起，Genant担任Synarc名誉主席和董事会成员。目前，Synarc与我公司签订了合同，测试仙灵骨葆胶囊（Xianling Gubao）的效果和安全性，以美国食品和药物管理局标准为准。他还是加州大学放射学、矫形外科、医学和流行病学名誉教授。他在Novartis、GlaxoSmithKline、Merck Sharp & Dohme、Amgen、Syeth、Bristol-Myers Squibb、Servier和Eli Lilly咨询委员会任职。Genant博士完成了巴尔的摩的约翰霍普金斯大学的实习，参与了部分the Osler Medical Service。他还完成了芝加哥大学放射科和医学住院医师培训，接下来的的30年，他都是UCSF肌肉骨骼放射学负责人。1986年他在UCSF放射科成立了骨质疏松症和关节炎研究小组，至今仍是其执行董事长。骨质疏松症和关节炎研究小组已被广泛公认是在非侵入性成像方法应用于骨质疏松症，关节炎和矫形手术最主要的研究来源。1967年，他获得伊利诺伊州芝加哥西北大学的医学学士学位。
Harry K. Genant has been an independent director of our company since March 21 2007. Dr. Genant is a co-founder of Synarc. Since 1998 Dr. Genant has been the chairman emeritus and member of the board of directors of Synarc. Currently, Synarc is contracted by us to test the efficiency and safety of Xianling Gubao under criteria established by the U.S. Food and Drug Administration. Dr. Genant is also professor emeritus of radiology, orthopedic surgery, medicine and epidemiology at the University of California at San Francisco, or UCSF. Dr. Genant serves on the advisory boards of Novartis, GlaxoSmithKline, Merck Sharp & Dohme, Amgen, Syeth, Bristol-Myers Squibb, Servier and Eli Lilly. Dr. Genant completed his internship at Johns Hopkins University in Baltimore, Maryland, where he was part of the Osler Medical Service. Dr. Genant also completed his residency training in medicine and in radiology at the University of Chicago, after which he was chief of musculoskeletal radiology at UCSF for the following 30 years. Dr. Genant founded the Osteoporosis and Arthritis Research Group in the Department of Radiology at UCSF in 1986 and remains its executive director. The Osteoporosis and Arthritis Research Group has been widely acclaimed as a leading source of research in noninvasive imaging methods applied to osteoporosis, arthritis and orthopedics. In 1967 Dr. Genant received his medical degree from Northwestern University in Chicago, Illinois. - Harry K. Genant，2007年3月21日起担任独立董事长。他是Synarc联合创始人。1998年起，Genant担任Synarc名誉主席和董事会成员。目前，Synarc与我公司签订了合同，测试仙灵骨葆胶囊（Xianling Gubao）的效果和安全性，以美国食品和药物管理局标准为准。他还是加州大学放射学、矫形外科、医学和流行病学名誉教授。他在Novartis、GlaxoSmithKline、Merck Sharp & Dohme、Amgen、Syeth、Bristol-Myers Squibb、Servier和Eli Lilly咨询委员会任职。Genant博士完成了巴尔的摩的约翰霍普金斯大学的实习，参与了部分the Osler Medical Service。他还完成了芝加哥大学放射科和医学住院医师培训，接下来的的30年，他都是UCSF肌肉骨骼放射学负责人。1986年他在UCSF放射科成立了骨质疏松症和关节炎研究小组，至今仍是其执行董事长。骨质疏松症和关节炎研究小组已被广泛公认是在非侵入性成像方法应用于骨质疏松症，关节炎和矫形手术最主要的研究来源。1967年，他获得伊利诺伊州芝加哥西北大学的医学学士学位。
- Harry K. Genant has been an independent director of our company since March 21 2007. Dr. Genant is a co-founder of Synarc. Since 1998 Dr. Genant has been the chairman emeritus and member of the board of directors of Synarc. Currently, Synarc is contracted by us to test the efficiency and safety of Xianling Gubao under criteria established by the U.S. Food and Drug Administration. Dr. Genant is also professor emeritus of radiology, orthopedic surgery, medicine and epidemiology at the University of California at San Francisco, or UCSF. Dr. Genant serves on the advisory boards of Novartis, GlaxoSmithKline, Merck Sharp & Dohme, Amgen, Syeth, Bristol-Myers Squibb, Servier and Eli Lilly. Dr. Genant completed his internship at Johns Hopkins University in Baltimore, Maryland, where he was part of the Osler Medical Service. Dr. Genant also completed his residency training in medicine and in radiology at the University of Chicago, after which he was chief of musculoskeletal radiology at UCSF for the following 30 years. Dr. Genant founded the Osteoporosis and Arthritis Research Group in the Department of Radiology at UCSF in 1986 and remains its executive director. The Osteoporosis and Arthritis Research Group has been widely acclaimed as a leading source of research in noninvasive imaging methods applied to osteoporosis, arthritis and orthopedics. In 1967 Dr. Genant received his medical degree from Northwestern University in Chicago, Illinois.
- David Ray White
-
David Ray White，2007年3月21日起担任独立董事长。他是美国德克萨斯州公共会计实践注册会计师。2006年1月到12月，他是White CPA（注册会计师事务所）所长，为小公司提供认证和税务咨询服务。1998年到2006年1月，他是休斯敦市Houston Galveston Area Council of Governments会计部经理，执行一项为美国地方政府服务的1.5亿美元的政府合作采购项目。1995年他获得贝勒大学的工商管理硕士，1980年他获得德克萨斯大学奥斯丁分校的工商管理学士学位。
David Ray White has been an independent director of our company since March 21 2007. Mr. White is a certified public accountant licensed to practice public accounting in Texas, U.S.A. From January to December 2006 Mr. White was the principal of White CPA, Certified Public Accounting Firm, offering attestation and tax consulting services to small companies. From November 1998 to January 2006 he was the accounting manager of Houston Galveston Area Council of Governments in Houston, Texas, performing accounting work for a US$150 million governmental cooperative purchasing program serving local governments in the United States. Mr. White received his MBA from Baylor University in 1995 and his BBA from The University of Texas at Austin in 1980. - David Ray White，2007年3月21日起担任独立董事长。他是美国德克萨斯州公共会计实践注册会计师。2006年1月到12月，他是White CPA（注册会计师事务所）所长，为小公司提供认证和税务咨询服务。1998年到2006年1月，他是休斯敦市Houston Galveston Area Council of Governments会计部经理，执行一项为美国地方政府服务的1.5亿美元的政府合作采购项目。1995年他获得贝勒大学的工商管理硕士，1980年他获得德克萨斯大学奥斯丁分校的工商管理学士学位。
- David Ray White has been an independent director of our company since March 21 2007. Mr. White is a certified public accountant licensed to practice public accounting in Texas, U.S.A. From January to December 2006 Mr. White was the principal of White CPA, Certified Public Accounting Firm, offering attestation and tax consulting services to small companies. From November 1998 to January 2006 he was the accounting manager of Houston Galveston Area Council of Governments in Houston, Texas, performing accounting work for a US$150 million governmental cooperative purchasing program serving local governments in the United States. Mr. White received his MBA from Baylor University in 1995 and his BBA from The University of Texas at Austin in 1980.
高管简历
中英对照 | 中文 | 英文- Xiaochun Wang
Xiaochun Wang，董事会主席和首席执行官。1997年5月起他是Tongjitang Pharmaceutical董事长；2001年2月起，他是Tongjitang Distribution董事长。2006年6月到2008年12月，他是贵州同济堂中药种植有限公司董事长。1989年Wang毕业于西南政法大学法律专业。
Xiaochun Wang is the chairman of our board of directors and our chief executive officer. Mr. Wang has also been the president of Tongjitang Pharmaceutical since May 1997 and a director of Tongjitang Distribution since February 2001. Mr. Wang served as a director of Guizhou Tongjitang Traditional Chinese Medicines Planting Co., Ltd. from June 2006 to December 2008. Mr. Wang received his bachelor's degree in law from the Southwest University of Political Science and Law in China in 1989.- Xiaochun Wang，董事会主席和首席执行官。1997年5月起他是Tongjitang Pharmaceutical董事长；2001年2月起，他是Tongjitang Distribution董事长。2006年6月到2008年12月，他是贵州同济堂中药种植有限公司董事长。1989年Wang毕业于西南政法大学法律专业。
- Xiaochun Wang is the chairman of our board of directors and our chief executive officer. Mr. Wang has also been the president of Tongjitang Pharmaceutical since May 1997 and a director of Tongjitang Distribution since February 2001. Mr. Wang served as a director of Guizhou Tongjitang Traditional Chinese Medicines Planting Co., Ltd. from June 2006 to December 2008. Mr. Wang received his bachelor's degree in law from the Southwest University of Political Science and Law in China in 1989.
- Justin Yan Chen
Justin Yan Chen，2006年5月16日起担任公司董事长，2006年11月起担任首席运营官。2001年，Chen先生加入中国海淀集团，2004年，他担任项目投资的负责人，负责该公司在中国的投资项目。1999年他获得英国兰开斯特大学工商管理硕士学位，1988年获得对外经济贸易大学经济学学士学位。
Justin Yan Chen has been a director of our company since May 16 2006 and our chief operating officer since November 2006. In 2001 Mr. Chen joined China Haidian and in 2004 served as the head of Project Investment, responsible for the company's investment projects in China. Mr. Chen received his MBA from Lancaster University in the United Kingdom in 1999 and bachelor's degree in economics from the University of International Business and Economics in China in 1988.- Justin Yan Chen，2006年5月16日起担任公司董事长，2006年11月起担任首席运营官。2001年，Chen先生加入中国海淀集团，2004年，他担任项目投资的负责人，负责该公司在中国的投资项目。1999年他获得英国兰开斯特大学工商管理硕士学位，1988年获得对外经济贸易大学经济学学士学位。
- Justin Yan Chen has been a director of our company since May 16 2006 and our chief operating officer since November 2006. In 2001 Mr. Chen joined China Haidian and in 2004 served as the head of Project Investment, responsible for the company's investment projects in China. Mr. Chen received his MBA from Lancaster University in the United Kingdom in 1999 and bachelor's degree in economics from the University of International Business and Economics in China in 1988.
- Ling Qin
Ling Qin，2006年6月起担任首席技术官。2005年起，Qin博士是香港中文大学的肌肉骨骼研究实验室教授和研究科学家。1994年9月他加入香港中文大学矫形外科及创伤部，1997年他成为该部门研究主管。1992年到1993年，他是瑞士AO / ASIF研究所博士后研究员。1993年，他被任命为美国骨科及创伤部、德国柏林自由大学Rudolf Virchow医学院研究员。Qin获得北京体育大学教育学士学位和机能解剖学硕士学位，1992年获得德国科隆体育大学实验形态学专业的体育科学博士学位。
Ling Qin has been our chief technology officer since July 2006. Since 2005 Dr. Qin has been a professor and research scientist in the Musculoskeletal Research Laboratory of the Chinese University of Hong Kong, Hong Kong. He joined the Department of Orthopaedics & Traumatology of the Chinese University of Hong Kong in September 1994 and has been this department's director of research since 1997. From 1992 to 1993 Dr. Qin worked as postdoctoral fellow in the AO/ASIF Research Institute in Switzerland. In 1993 he was employed as a research scientist by the Department of Orthopaedics and Traumatology, Medical School of Rudolf Virchow at the Free University of Berlin, Germany. Dr. Qin received his bachelor degree in education and master degree in education from the Beijing University of Physical Education with a major in functional anatomy, and doctorate degree in sports sciences in 1992 from the German Sports University Cologne, where he majored in experimental morphology.- Ling Qin，2006年6月起担任首席技术官。2005年起，Qin博士是香港中文大学的肌肉骨骼研究实验室教授和研究科学家。1994年9月他加入香港中文大学矫形外科及创伤部，1997年他成为该部门研究主管。1992年到1993年，他是瑞士AO / ASIF研究所博士后研究员。1993年，他被任命为美国骨科及创伤部、德国柏林自由大学Rudolf Virchow医学院研究员。Qin获得北京体育大学教育学士学位和机能解剖学硕士学位，1992年获得德国科隆体育大学实验形态学专业的体育科学博士学位。
- Ling Qin has been our chief technology officer since July 2006. Since 2005 Dr. Qin has been a professor and research scientist in the Musculoskeletal Research Laboratory of the Chinese University of Hong Kong, Hong Kong. He joined the Department of Orthopaedics & Traumatology of the Chinese University of Hong Kong in September 1994 and has been this department's director of research since 1997. From 1992 to 1993 Dr. Qin worked as postdoctoral fellow in the AO/ASIF Research Institute in Switzerland. In 1993 he was employed as a research scientist by the Department of Orthopaedics and Traumatology, Medical School of Rudolf Virchow at the Free University of Berlin, Germany. Dr. Qin received his bachelor degree in education and master degree in education from the Beijing University of Physical Education with a major in functional anatomy, and doctorate degree in sports sciences in 1992 from the German Sports University Cologne, where he majored in experimental morphology.
- Charles Wang
Charles Wang，2008年12月起担任首席财务官。1999年6月到2008年12月，他担任Asia Renal Care, Ltd（亚太地区一家领先的医疗服务供应商）首席财务官。1999年6月前，他是Hanson Pacific Ltd（Hanson PLC亚太总部）财务经理 负责组织和执行合并、收购和合资公司事务。在他的财务生涯之前，他是PricewaterhouseCoopers（香港）企业财务经理和 Kingston Smith特许会计事务所审计副经理。他获得英国利兹大学经济学与会计学荣誉学位，1991年起成为英格兰和威尔士特许会计师协会成员。
Charles Wang has been our chief financial officer since December 2008. From June 1999 to December 2008 he served as Chief Financial Officer at Asia Renal Care, Ltd., a leading healthcare service provider in the Asia-Pacific region. Prior to June 1999 Mr. Wang was the Finance Director at Hanson Pacific Ltd., the Asia Pacific Headquarters of Hanson PLC, where he structured and executed mergers, acquisitions and joint venture transactions. Early in his financial career, Mr. Wang was Corporate Finance Manager at PricewaterhouseCoopers (Hong Kong), and Assistant Audit Manager at Kingston Smith Chartered Accountants. Mr. Wang received his B.A. with honors in Economics and Accounting from the University of Leeds, England, and has been a member of the Institute of Chartered Accountants of England and Wales since 1991.- Charles Wang，2008年12月起担任首席财务官。1999年6月到2008年12月，他担任Asia Renal Care, Ltd（亚太地区一家领先的医疗服务供应商）首席财务官。1999年6月前，他是Hanson Pacific Ltd（Hanson PLC亚太总部）财务经理 负责组织和执行合并、收购和合资公司事务。在他的财务生涯之前，他是PricewaterhouseCoopers（香港）企业财务经理和 Kingston Smith特许会计事务所审计副经理。他获得英国利兹大学经济学与会计学荣誉学位，1991年起成为英格兰和威尔士特许会计师协会成员。
- Charles Wang has been our chief financial officer since December 2008. From June 1999 to December 2008 he served as Chief Financial Officer at Asia Renal Care, Ltd., a leading healthcare service provider in the Asia-Pacific region. Prior to June 1999 Mr. Wang was the Finance Director at Hanson Pacific Ltd., the Asia Pacific Headquarters of Hanson PLC, where he structured and executed mergers, acquisitions and joint venture transactions. Early in his financial career, Mr. Wang was Corporate Finance Manager at PricewaterhouseCoopers (Hong Kong), and Assistant Audit Manager at Kingston Smith Chartered Accountants. Mr. Wang received his B.A. with honors in Economics and Accounting from the University of Leeds, England, and has been a member of the Institute of Chartered Accountants of England and Wales since 1991.